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Introduction
C-reactive protein (CRP) is a marker of chronic low-grade inflammation and high CRP levels are linked to increased risk of mortality (1) and a range of disorders (2) , including coronary heart disease and stroke (3) . The largest genome-wide association study (GWAS) on CRP levels to date identified 18 independent genetic loci (4) . However, several other molecular mechanisms such as epigenetic modifications, which are downstream of genetic variation, might also be involved in CRP functioning.
Epigenetic modifications, including DNA methylation, can affect gene expression (5) without changing the DNA sequence. To unravel the role of DNA methylation in chronic inflammation, Ligthart et al. (6) performed an epigenome-wide association study (EWAS) on serum CRP levels and identified 58 DNA methylation markers in a large panel of individuals of European descent (n=8,863) and replicated in a panel of African Americans (n=4,111).
However, currently it is not well understood whether DNA methylation is a cause or consequence of changes in CRP levels.
In Mendelian randomization (MR) genetic variants are used as instrumental variables to assess the causality of an association (7) (8) (9) . Using genetic variants as instruments can reduce biases, which arise due to confounding or reverse causation. For an instrument to be valid, it must be i) reliably associated with the exposure; ii) associated with the outcome only through the exposure and iii) independent of confounders that influence the exposure and the outcome. To address the current question, we made use of genetic variants that act independently as proxies for CRP levels and for DNA methylation markers.
With respect to DNA methylation data, an MR framework has been proposed (Relton & Davey Smith 2012) and has, for instance, been applied to investigate the causal relationship between HIF3A-linked DNA methylation and body mass index. In that study, the authors failed to identify a causal effect of DNA methylation on body mass index (10) . With relevance to CRP and epigenome-wide data, a recent epigenome-wide association study identified CpG sites that putatively influenced cardiovascular disease risk traits, including CRP (11) . The authors reported that some cardiovascular traits are influenced by altered DNA methylation, but evidence specific to CRP was weak.
In this study, we applied MR to infer causality and the direction of effect between CRP and epigenome-wide DNA methylation markers.
Results

Causal effect of CRP on epigenome-wide DNA methylation
To investigate whether CRP is causally linked to DNA methylation at an epigenomewide level, we used 18 SNPs, which have been shown to associate with CRP levels (4), as genetic instruments. Genotype-exposure estimates were taken from the same study. To derive genotype-outcome estimates, the effect of these 18 SNPs on epigenome-wide DNA methylation was tested in a sample of 1,616 participants from the ARIES study (see "MR sample" in Table 1 ).
Using a range of MR methods, including IVW, WM and MR-Egger, to combine the effect from individual SNPS, we found no evidence for an association with single site DNA methylation at an epigenome-wide threshold (Figure 2 and Supplementary Material (SM) Table S1). A lambda of 0.99 and the inspection of the QQ plot (SM S1A) provided little evidence for population sub-structures or genotyping errors. We also failed to identify differentially methylated regions (i.e., a region of the genome in which several neighbouring CpG sites show differential methylation, SM Figure S1B , and SM Figure S2 for CpG-specific regional plots and gene track annotation). Furthermore, we found no evidence for causal associations restricting ourselves to the 58 CpG sites that were linked to CRP in a previous EWAS (6) . In detail, there was no correlation between effect sizes of the EWAS and MR analyses and no CpG site passed a threshold correction for 58 tests (SM Table S2 and SM Figure S3 for CpG-specific regional plots).
Replication of CRP-linked DNA methylation effects on CRP
As a validation analysis, we first sought to confirm previous CRP EWAS findings in our dataset (see "Subset with CRP data" in Table 1 ). We identified a strong correlation between our and previously reported effect sizes of the 58 CpGs sites (rho = 0.83, p = 9.49*10 -16 , 95% CI [0.73, 0.90]; SM Figure S4 ). For 55 of 58 CpGs, the sign of effect was consistent between the Ligthart et al. (6) results and our own (SM Table S2 ).
Causal relationship of CRP-linked DNA methylation on CRP
As a next step, we tested for a causal effect of DNA methylation on CRP, separately in the mothers and offspring, as mQTLs were identified specific to each group and time point. mQTLs could be identified (via mqtldb.org) for 13 of the 58 CpG sites that were originally identified to be linked to CRP. mQTLs for 11 of these 13 CpGs, linked to eight genes, were available in the summary data from Dehghan et al. (4) and subsequently analysed in an MR framework (see SM Figure S5 for a flowchart and further details). In the mothers, one CpG (cg08548559) was tagged by two independent mQTLs, while in both mothers and offspring one mQTL (rs12677618) tagged two different CpG sites. For Table S3 ). The sign of the putative causal effects for these three CpG sites was opposite to the observed associations reported in the current study and in Ligthart et al. (6) .
Additional analyses
The three putatively causal CpG sites were each instrumented by only a single genetic variant. It is hence possible that such an mQTL is merely in linkage disequilibrium with another variant that affects CRP levels. To address this, we carried out a colocalization test for each CpG and all SNPs within a 1MB window of the instrumental mQTL. In each case, results provided strong evidence for one shared causal variant, given posterior probabilities for this scenario between 77.4 -98.2% (SM Table S7 ). Of note, these analyses were based on a small number of SNPs (range: 2-57) and did not allow us to distinguish between mediation (SNP to methylation to CRP) and horizontal pleiotropy (SNP affecting methylation and CRP via independent biological pathways).
As CRP is predominantly expressed in the liver, but DNA methylation was obtained from blood cells. We were interested to see whether the three genes linked to the putatively causal CpG sites were expressed more strongly in liver tissue compared to the remaining five genes with no causal CpG sites. We therefore investigated gene expression profiles of all eight genes that linked to the investigated 11 CpGs, using public data available via gtexportal.org. Gene expression of TMEM49 (median transcript per million (TPM) = 29.54) and BCL3 (median TPM = 100.40) was highly elevated in the liver compared to the other genes (range of median TPM: 0 -4.24; SM Figure S6 ), suggesting a relevance for these genes in liver tissue.
As a last step, we investigated whether the five SNPs, which were used as instruments for the three putatively causal CpG sites, were also linked to BMI, as i) BMI and CRP are closely linked (12) and ii) BMI has been shown to influence DNA methylation (13) .
An association of the instrumental SNPs with BMI could indicate a potential violation of MR assumptions; however, a look-up of these SNPs in a recent GWAS on BMI (14) provided no clear evidence associations (SM Table S8 ).
Discussion
Applying MR to infer causality and the direction of effect between CRP and epigenomewide DNA methylation, we found little evidence that CRP causally impacts DNA methylation levels. Instead, for a selection of CpG sites, DNA methylation appeared to influence CRP levels. For these sites, which were linked to the genes TMEM49, BCL3 and MIR21, the putative causal effect on CRP was opposite in sign to the observed associations, suggestive of potential negative feedback mechanisms.
Several studies have reported associations between DNA methylationeither in candidate genes such as AIM2 or epigenome-wideand CRP levels (6, 11, 15) . Most notably, the largest epigenome-wide meta-analysis so far identified and replicated 58 CpG sites. Interestingly, while 51 of these 58 sites were also linked to at least one cardiometabolic trait, only 9 sites were also associated with whole blood gene expression levels in cis. While the authors were careful to not draw conclusions about the causality of effects, these results suggest that the route from DNA methylation to gene expression and disease might be more complex in some contexts. Miller et al. (15) followed up on these findings and focussed in particular on AIM2 DNA methylation in relation to CRP in a sample of US military veterans with and without post-traumatic stress disorder (PTSD). They found that AIM2 DNA methylation was lower in PTSD cases and also negatively correlated with CRP levels, which itself was elevated in patients. Specifically, the authors also reported an indirect effect of PTSD on CRP via AIM2 DNA methylation, indicating that in the case of AIM2, DNA methylation might be upstream of CRP. We were not able to investigate the causal effects of AIM2 DNA methylation in our study, as we were unable to identify an mQTL for the underlying CpG. However, consistent with both previous studies (6, 15) , AIM2cg10636246
DNA methylation was negatively associated with CRP in our study, providing an overall agreement in observational effects between studies. Additionally, in line with Miller et al.
(15), we found that for a selection of CpG sites, DNA methylation appeared to influence CRP levelsrather than the reverse. Similarly, Richardson et al. (11) reported that some genetic influences on cardiovascular traits were putatively mediated through changes in DNA methylation, which itself displayed downstream effects on gene expression. However, in that study the authors employed a one-sample MR approach that can be less powerful than a two-sample MR analysis and indeed, the evidence specifically to CRP was weak, not passing the genome-wide threshold applied in the current study. Considering that DNA methylation appeared to influence CRP levels in only a selection of CpG sites and that not all of these CpG sites were among the most strongly associated sites in the original EWAS indicates that the suggestive pathway from DNA methylation to CRP might be CpG-specific and not a general rule.
Our findings add to several studies that focussed on the interplay between DNA methylation, gene expression and protein levels. Ng et al. (16) tested for associations between epigenetic markers (including DNA methylation and histone modifications) and gene expression and found that 9% of association sets followed an epigenetic mediation model, which was defined by a propagation path from genetic variants to gene expression via epigenetic modification. Only 3% of associations showed evidence for the reverse path, where gene expression impacts the epigenome.
Contrary to this report, Ahsan et al. (17) investigated the interplay between DNA methylation and 121 protein biomarkers for inflammation, cancer and cardiovascular disease (although not CRP). They found that for 22% (i.e., n=27) of the studied proteins, biomarker levels appeared to influence DNA methylation, rather than the reserve. The authors hence argued that genetic variants, environmental exposures or secondary effects of disease impact DNA methylation, which itself might not play a direct role in the regulation of these biomarkers. Taken together with the current results, findings suggest that DNA methylation in certain genes may lie upstream of gene expression and protein levels of some inflammation-related biomarkers such as CRP, but that this finding cannot be generalized overall.
For three CpGs, we identified putative causal effects on CRP levels. Two CpGs were within 2,500 base pairs from each other, located in the proximity of the genes TMEM49 and MIR21. TMEM49 is a transmembrane protein, which is expressed in most tissues, and plays a role in autophagy, an intracellular degradation process. TMEM49 has been linked to pancreatitis, apoptosis and cell-cell adhesion. Aside its association with CRP (6), TMEM49
DNA methylation associated with two inflammatory markers (soluble tumor necrosis factor receptor 2 andto a lesser degreeinterleukin-6) prior to and 6 months after radiation therapy in a small sample of patients with breast cancer (18) . Similarly, expression of miR-21, located in the intron of TMEM49 (19) , has been observed to be responsive to inflammation (20) (21) (22) .
BCL3 is a proto-oncogene candidate. It has been associated with anti-inflammatory response in diseased pancreatic rodent and human tissues (23) and BCL3 suppression increases the release of the pro-inflammatory cytokines IL-8 and IL-17 in T cell lymphoma (24) . However, the link between BCL3 DNA methylation and CRP levels, which was reported In summary, our findings further support the role of DNA methylation linked to the genes TMEM49, MIR21 and BCL3 in inflammatory processes. Their function in inflammation is most likely through an upregulating effect on serum CRP.
Of note, the sign of the putative causal effects identified in the current study were opposite in sign to the observational associations reported both in our study as well as in previous studies (6, 25) . Discrepancies between observational and causal associations have been reported repeatedly in the literature. Much attention was given to the findings that vitamin ß-carotene deficiency apparently does not increase the risk of smoking-related cancers (26) or that there does not appear to be a causal link between vitamin C or E and coronary heart disease (27, 28) , despite promising observational associations in all three cases. Measurement error and residual confounding are just two reasons that can explain this discrepancy and are discussed at length elsewhere (7) . It is however noteworthy that in the case of DNA methylation (linked to TMEM49, MIR21 and BCL3) and CRP, observational findings between studies were in agreement despite cross-study differences in which were based on whole-blood tissue. It is possible that a negative feedback mechanism could account for the discrepancy in effect signs. In detail, it is conceivable that DNA methylation in the reported genes lead to an upregulation of CRP levels (i.e., the causal effect), which also results in a cascade of inflammatory-related processes (such as altered natural killer cell or CD8T cell counts) that might affect measurements of DNA methylation in whole blood (i.e., the observed effect). However, further studies are necessary to draw more definite conclusions.
The findings of this study should be considered in light of the following limitations. First, although we employed a two-sample MR setting to benefit from findings based on large, well-powered studies, mQTLs were identified in a sample of 837 adolescents and 742 mothers in middle age. It is hence possible that the mQTLs used in our study represent less optimal instruments for DNA methylation. In fact, only four of the 11 mQTLs used in our study (and none of the three CpGs linked to TMEM49, MIR21 or BCL3) overlapped with those identified in Ligthart et al. (6) using data from the Framingham Heart and the Rotterdam study. It remains to be seen how well our findings replicate using mQTLs that are based on larger samples.
Second, violations of MR assumptions such as horizontal pleiotropy (i.e., variants influencing CRP through other pathways than the CpG) can limit the conclusions drawn in this study. In the case of DNA methylation, we had only one instrument available, which restricted our ability to evaluate bias due to horizontal pleiotropy. However, to reduce the risk of horizontal pleiotropy we used mainly cis-regulatory SNPs (only two mQTLs were more than 1 Mb away from their CpG). This greatly reduces the likelihood of pleiotropic effects.
We also conducted colocalization analysis for putative MR associations, and while not sufficient, demonstrating shared genetic variants between a putative exposure and outcome is necessary for a causal association.
Third, we did not investigate other markers of inflammation. For instance, biomarkers upstream of CRP include IL-6 (29) , which stimulates the production of CRP. A small epigenome-wide study (30) Reassuringly, the majority of these CpGs exhibited similar observed relationships (ie.
positive or negative correlation) as previously reported for CRP, but an investigation of causal associations is still lacking.
In summary, we found no evidence that CRP causally impacts DNA methylation levels.
Instead, for a selection of CpG sites, DNA methylation appeared to influence CRP levels in a direction that was opposite to the observed association. Our findings further support previous findings that see DNA methylation as one factor on the causal pathway to inflammation.
Materials and Methods
Overview
We carried out a two-sample MR analysis (31, 32) Figure 1 ), we used genetic variants (n=18) that have been reported to be robustly associated with CRP levels (4) as proxies for CRP levels and explored their effect on epigenome-wide DNA methylation using the ARIES resource (see below for further details). To examine the reverse association (DNA methylation causally influencing CRP levels; panel 2 in Figure 1 ), we studied CpG sites (n=58) that have been linked to CRP levels in a recent EWAS (6) . We first investigated how well these previous findings could be replicated in our cohort by performing an association analysis on these CpG sites and CRP measures (panel 2a in Figure 1 ). Thento investigate potentially causal effectswe identified underlying methylation quantitative trait loci (mQTLs) for these CpG sites via mqtldb.org (see below for further details) and combined this with CRP GWAS summary data (4) to inspect causal pathways within a two-sample MR framework (panel 2b in Figure 1 ).
Genetic instruments for CRP levels
Summary statistics from the to-date largest GWAS of CRP levels were based on an analysis of 66,185 participants from 15 population-based cohort studies with a replication in 16,540 participants from ten independent studies (4). All participants were of European ancestry. Genome-wide scans on natural log-transformed CRP levels (mg/L) were run controlling for age, sex as well as site and family structure, if necessary. Results were subsequently corrected for genomic inflation. Eighteen SNPs passed genome-wide threshold and were used as genetic instruments for CRP in the current analysis.
Association of 18 CRP index genetic variants with epigenome-wide DNA methylation Sample
We used CRP, genetic and epigenetic data from participants, which were drawn from Measures Peripheral blood samples were collected and analysed from mothers and children at the time, when the children were adolescents (mean ageoffspring = 17.1, mean agemothers = 47.7). DNA methylation data was measured using the Illumina Infinium HumanMethylation450K BeadChip. Samples failing quality control (average probe P value ≥0.05, those with sex or genotype mismatches) were excluded from further analysis and scheduled for repeat assay, and probes that contained <95% of signals detectable above background signal (detection P value <0.05) were excluded from analysis (n=1,113) leaving 481,742 CpGs to be analysed. Methylation data were pre-processed using R software, with background correction and functional normalization performed using the meffil pipeline (36) .
For CRP measurements, blood samples were collected from participants who were instructed to fast overnight if their assessment was in the morning, or at least for 6 h if the assessment was in the afternoon. Blood samples were immediately spun, frozen and stored at -80 degrees Celsius, and analysed within 3-9 months of blood sampling with no freezethaw cycles in between. High sensitivity CRP was measured by automated particleenhanced immunoturbidimetric assay (Roche UK, Welwyn Garden City, UK).
Genetic data was based on the Illumina HumanHap550 quad genome-wide SNP genotyping platform (Illumina Inc, San Diego, USA). Imputation was performed using a joint reference panel using variants discovered through whole genome sequencing in the UK10K project along with known variants taken from the 1000 genomes reference panel. Novel functionality was developed in IMPUTE2 (37) 
Replication of CRP EWAS findings
Fifty-eight CRP-linked CpGs at a genome-wide threshold were identified in a metaanalysis (6) of a study in a large European population (n = 8,863) and a trans-ethnic replication in African Americans (n = 4,111).
To verify how well these recent CRP EWAS findings could be replicated in our cohort, we performed an association analysis on these CpG sites in the mothers and children for which CRP measures were available (n=1,403 CpGs. mQTLs that were linked to the same CpG were subsequently pruned using the LDclumping function in MR-Base (38) . For two CpGs, none of the identified mQTLS were present in the CRP GWAS summary data, leaving 11 CpGs in the final analysis.
Mendelian randomisation analysis
All summary statistics were harmonized using the TwoSampleMR R package, which is part of the MR-Base online platform (38) . Two-sample MR analyses were then undertaken using the TwoSampleMR and MendelianRandomization R packages (39) . Linear regression analysis of SNP-CRP and SNP-CpG association were carried out using an inverse-variance weighted (IVW), weighted median (WM) and MR-Egger methods. To identify differentially methylated regions (DMRs), we used the Python module comb-p (40) , which is designed to identify peaks in a vector of spatially correlated P values by grouping correlated CpGs in a 500-bp sliding window with a stepsize of 50.
To test for causal effects of CRP-linked DNA methylation on CRP, we applied the Wald ratio method (41) , as for most CpGs only one mQTL was available for analysis after LD pruning and data harmonization. Colocalization tests were carried out for fine mapping purposes using the coloc.abf function in the coloc R package (42) . This allowed us to examine whether mQTLs were in linkage disequilibrium (LD) with other SNPs that might impact CRP levels. 
